STAT5 as a CML target: STATinib therapies?

Blood

Volumn 117, Issue 12, 2011, Pages 3252-3253

  Turhan, Ali G ^a  

^a Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; MESSENGER RNA; NILOTINIB; PIMOZIDE; PROTEIN TYROSINE KINASE INHIBITOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

APOPTOSIS; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL;

EID: 79953084067     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-332569     Document Type: Note

References (13)

1. Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421-3429.
2. WarschW,Kollmann K, Eckelhart E, et al. HighSTAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117(12): 3409-3420.
3. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation andDNAbinding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996; 183(3):811-820. (Pubitemid 26113953)
4. Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation andDNAbinding activity of multiple specific STAT family members. J Biol Chem. 1996;271(49):31704-31710. (Pubitemid 26408636)
5. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13(2): 247-254.
6. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000;96(6):2269-2276.
7. Slupianek A, Schmutte C, Tombline G, et al. BCR/ ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8(4):795-806. (Pubitemid 33030213)
8. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000;95(6):2118-2125. (Pubitemid 30151654)
9. Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev. 2009 Apr 15;(2): CD006996.
10. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6):1054-1061.
11. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007; 21(5):926-935. (Pubitemid 46672068)
12. Corbin AS, Agarwal A, Loriaux M, Cortes J, DeiningerMW,Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
13. O'Hare T, DeiningerMW,Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17(2):212-221.